The Drug Enforcement Administration just extended Covid-era telemedicine flexibilities for prescribing controlled substances through December 31, 2026, buying the agency more time to finalize permanent rules that will shape the future of virtual care. For ketamine telehealth providers — many of which have built national, mail-order businesses — this move offers temporary relief, but long-term…...
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
